- Home
- PMEC vs HOWL Comparison
PMEC vs HOWL Comparison
Compare PMEC & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- HOWL
- Stock Information
- Founded
- PMEC 1984
- HOWL 2017
- Country
- PMEC Singapore
- HOWL United States
- Employees
- PMEC N/A
- HOWL N/A
- Industry
- PMEC
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- HOWL Health Care
- Exchange
- PMEC Nasdaq
- HOWL Nasdaq
- Market Cap
- PMEC 46.1M
- HOWL 53.4M
- IPO Year
- PMEC 2023
- HOWL 2021
- Fundamental
- Price
- PMEC N/A
- HOWL $1.07
- Analyst Decision
- PMEC
- HOWL Strong Buy
- Analyst Count
- PMEC 0
- HOWL 3
- Target Price
- PMEC N/A
- HOWL $8.33
- AVG Volume (30 Days)
- PMEC 52.6K
- HOWL 612.4K
- Earning Date
- PMEC 01-01-0001
- HOWL 08-07-2025
- Dividend Yield
- PMEC N/A
- HOWL N/A
- EPS Growth
- PMEC N/A
- HOWL N/A
- EPS
- PMEC N/A
- HOWL N/A
- Revenue
- PMEC $74,310,000.00
- HOWL $1,143,000.00
- Revenue This Year
- PMEC N/A
- HOWL N/A
- Revenue Next Year
- PMEC N/A
- HOWL N/A
- P/E Ratio
- PMEC N/A
- HOWL N/A
- Revenue Growth
- PMEC 3.94
- HOWL N/A
- 52 Week Low
- PMEC $0.49
- HOWL $0.60
- 52 Week High
- PMEC $1.49
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- PMEC 68.28
- HOWL 43.95
- Support Level
- PMEC $1.26
- HOWL $1.02
- Resistance Level
- PMEC $1.46
- HOWL $1.12
- Average True Range (ATR)
- PMEC 0.12
- HOWL 0.09
- MACD
- PMEC 0.03
- HOWL -0.03
- Stochastic Oscillator
- PMEC 97.96
- HOWL 16.67
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.